The global clinical oncology next generation sequencing market size was valued at USD 628.45 million in 2025 and is projected to grow from USD 695.95 million in 2026 to USD 1574.02 million by 2034, registering a CAGR of 10.74% during the forecast period from 2026 to 2034. North America dominated the clinical oncology next-generation sequencing market with a market share of 42.35% in 2025.
Clinical oncology next-generation sequencing (NGS) refers to the use of advanced sequencing technologies to analyze tumor DNA and RNA for identifying genetic mutations, biomarkers, and other molecular alterations. It supports cancer diagnosis, tumor profiling, treatment selection, companion diagnostics, and disease monitoring, enabling more personalized and precision-based oncology care.
Download a Free Sample To learn more about this report,
Liquid Biopsy NGS Is Expanding Blood-Based Cancer Profiling
The clinical oncology next-generation sequencing market trends show that liquid biopsy NGS is shifting cancer profiling toward less-invasive blood-based testing using circulating cell-free DNA. This transition is expanding molecular profiling when tissue samples are difficult to obtain, with FDA-approved Guardant 360 Liquid CDx using plasma cfDNA to analyze 741 genes for multiple genomic alterations. The outcome is broader use of blood-based NGS for treatment selection and tumor profiling.
RNA Sequencing Is Expanding Detection of Clinically Relevant Gene Fusions
RNA sequencing is expanding NGS beyond DNA mutations toward the detection of gene fusions and splice variants. This transition is strengthening the identification of clinically relevant alterations, with FDA-authorized TruSight Oncology Comprehensive detecting fusions in 24 genes and splice variants in one gene from RNA. The outcome is more comprehensive molecular profiling for targeted treatment decisions in solid tumors.
Broader Use of Companion Diagnostics and Availability of Targeted Cancer Therapies Drive Market
Companion diagnostics are increasingly used to identify patients whose tumors contain biomarkers linked to specific targeted treatments. NGS-based testing can evaluate multiple genomic biomarkers in a single workflow, allowing clinicians to select appropriate therapies without requiring separate tests for each alteration. This clinical connection between biomarker identification and treatment selection creates recurring demand for NGS-based diagnostic testing.
The expanding availability of targeted cancer therapies strengthens this demand by increasing the need for molecular characterization before treatment decisions. NGS enables broader genomic assessment from limited tumor samples, helping identify alterations that may guide therapy selection across different cancer types. As more targeted treatments enter clinical practice, the need for reliable genomic testing supports continued adoption of NGS platforms and clinical sequencing services.
Complex Data Interpretation and Limited Tissue Sample Quality Restrain Clinical Oncology Next-Generation Sequencing Market Expansion
Complex genomic datasets generated through NGS require specialized bioinformatics expertise and clinical interpretation to identify actionable alterations accurately. Limited availability of trained professionals and interpretation complexity can increase workflow requirements, delay reporting, and slow the integration of NGS into routine oncology care.
Limited availability of high-quality tissue samples can reduce the reliability of sequencing results when samples contain insufficient tumor material or degraded DNA. Additional sample collection or repeat biopsies can increase clinical burden and delay genomic testing, restricting the wider adoption of NGS in oncology.
NGS-Based Tumor Profiling for Rare Cancers and Tumor-Normal Sequencing Create New Market Opportunities
Molecular diagnostic companies, oncology laboratories, and sequencing providers can develop specialized NGS panels for rare cancers where diverse genomic profiles require focused testing solutions. Companies such as Foundation Medicine and Tempus can generate revenue through disease-specific panels, sequencing services, and clinical interpretation while supporting clinical oncology next-generation sequencing market growth.
Oncology laboratories, genomic testing companies, and sequencing providers can expand tumor-normal sequencing workflows that compare tumor DNA with matched normal DNA to distinguish acquired alterations from inherited variants. Companies such as Illumina and QIAGEN can generate revenue through sequencing platforms, sample-preparation products, and bioinformatics solutions, creating additional commercial opportunities.
Inconsistent Clinical Adoption and Fragmented Genomic Knowledge Hinder Market Growth
Inconsistent clinical adoption across healthcare settings creates uneven demand for NGS testing, as hospitals and oncology practices differ in testing workflows, institutional policies, and access to genomic services. This variation can slow broader integration of NGS into routine cancer care and make market expansion across healthcare systems more difficult. In 2025, a community-oncology study identified differences in testing practices and organizational barriers affecting NGS implementation.
Fragmented genomic knowledge bases can make it difficult for laboratories and clinicians to consistently interpret and apply rapidly expanding genomic evidence. Differences in databases, annotation methods, and evidence classifications can complicate the use of NGS findings across clinical settings and increase the effort required to maintain reliable genomic resources. Thus, fragmented genomic knowledge bases become a major issue among key players.
The companion diagnostics segment accounted for a share of 44.87% in 2025 and is expected to grow at a CAGR of 16.12% during the forecast period 2026-2034, supported by increasing use of genomic information to guide targeted cancer therapies and treatment selection. The screening segment supports the identification of cancer-related genomic alterations at an early stage, while the others segment covers additional clinical applications of NGS in oncology.
Request Customizationto receive a tailored report.
The NGS sequencing segment accounted for a share of 45.39% in 2025, owing to its central role in generating genomic data for clinical oncology applications. The NGS pre-sequencing segment supports sample preparation and library construction before sequencing.
The NGS data analysis segment is expected to grow at a CAGR of 16.84% during the forecast period 2026-2034, driven by increasing demand for advanced analysis of complex genomic datasets. The segment enables the interpretation of sequencing results to identify clinically relevant genetic information.
The targeted sequence and re-sequencing segment accounted for a share of 46.64% in 2025, supported by its ability to focus genomic analysis on specific cancer-related regions and variants. The whole exome sequencing segment focuses on protein-coding regions to support the identification of clinically relevant genetic alterations.
The whole genome sequencing segment is expected to grow at a CAGR of 15.82% during the forecast period 2026-2034, propelled by increasing demand for comprehensive genomic profiling across oncology research and clinical applications.
The diagnostic laboratories segment accounted for a share of 47.26% in 2025 and is expected to grow at a CAGR of 15.74% during the forecast period 2026-2034, due to their extensive role in molecular testing, genomic analysis, and cancer diagnosis.
The hospitals segment supports clinical oncology testing and patient management, while the other segment includes additional healthcare and research settings that use NGS technologies.
Speak to an Analystto discuss market opportunities.
The North America clinical oncology next generation sequencing market accounted for the largest regional share of 42.35% in 2025, supported by advanced molecular diagnostics infrastructure, high adoption of precision oncology, strong cancer research activity, and established reimbursement pathways for genomic testing. The U.S. clinical oncology next-generation sequencing market is driven by projections that the number of new cancer cases in the U.S. could reach approximately 1.88 million by 2030, while metastatic breast cancer prevalence is projected to reach 246,194 cases by 2030, increasing the need for genomic profiling and precision oncology diagnostics.
The Canada clinical oncology next-generation sequencing market is fuelled by Canadian Cancer Statistics’ projection of 254,100 new cancer cases in 2026, while pancreatic and uterine cancers continue to show rising incidence trends, increasing the need for molecular profiling and precision oncology diagnostics.
Unlock Regional Insightsto access country-level data, & regional trends.
The Asia Pacific clinical oncology next-generation sequencing market is expected to grow at a CAGR of 17.38% during the forecast period 2026–2034, showcasing the fastest-growing regional market, propelled by the rising cancer burden, expanding molecular diagnostics infrastructure, increasing adoption of precision medicine, and growing integration of genomic technologies into oncology care across the region. The Japan clinical oncology next-generation sequencing market is supported by Japan’s National Cancer Center projections that average annual cancer incidence will reach about 1.165 million cases during 2035–2039, while the Ministry of Health, Labour and Welfare envisions expanding whole-genome analysis to around 300,000–400,000 patients annually, supporting future demand for NGS-based cancer genomic testing.
The China clinical oncology next-generation sequencing market is driven by China’s National Health Commission target to achieve a 46.6% overall five-year cancer survival rate by 2030, alongside plans to expand cancer screening, early diagnosis, and standardized treatment, increasing the need for genomic testing and precision oncology technologies.
The Europe clinical oncology next-generation sequencing market accounted for a 27.18% share and is expected to grow at a CAGR of 6.68% during the forecast period 2026–2034, fuelled by the EU Cancer Mission’s goal to ensure 90% of eligible cancer patients have access to comprehensive cancer infrastructures by 2030 and initiatives promoting next-generation sequencing for personalised cancer diagnosis and treatment. The U.K. clinical oncology next-generation sequencing market is supported by the government’s plan for genomic insights and predictive analytics to inform up to 50% of healthcare interactions by 2035, while Genomics England is expected to host more than 500,000 genomes by 2030, strengthening the infrastructure for genomic testing and precision oncology.
The Germany clinical oncology next-generation sequencing market is propelled by the government’s genomeDE pilot project, which will run for at least five years from 2024 to integrate genomic medicine into healthcare for oncological diseases, while health-data infrastructure is targeted to become linkable with cancer registries and genomeDE by 2028, supporting wider adoption of genomic testing in oncology.
The clinical oncology next-generation sequencing market competitive landscape is moderately consolidated, with competition comprising NGS platform developers, molecular diagnostics companies, genomic profiling specialists, analytical technology providers, and precision oncology companies. Key players such as Illumina, Inc., Thermo Fisher Scientific Inc., Agilent Technologies, Inc., Hoffmann-La Roche Ltd., and QIAGEN N.V. collectively are estimated to account for approximately 55–60% of the global clinical oncology next-generation sequencing market share.
Established players compete primarily on sequencing accuracy, assay breadth, clinical validation, and bioinformatics capabilities. Emerging and specialized players in the clinical oncology next-generation sequencing market ecosystem compete through comprehensive genomic profiling, liquid biopsy solutions, targeted oncology panels, and application-specific sequencing technologies. Illumina offers oncology-focused sequencing systems and panels, while Foundation Medicine provides NGS-based comprehensive genomic profiling across hundreds of cancer-related genes for clinical oncology applications.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Organ Preservation Market Size, Share, Growth, Analysis, Report, 2034
Bacteriophage Market Size, Share, Growth, Analysis, 2034
Epigenetics Market Size, Share, Growth, Analysis, Report, 2034
Biobanking Market Size, Share, Growth, 2034
Cell Therapy Manufacturing Market Size, Share, Growth, 2034
Autoimmune Disease Diagnostics Market Size, Share, Growth, 2034
We are featured on:
sales@straitsresearch.com